|Day Low/High||189.49 / 191.48|
|52 Wk Low/High||163.31 / 201.23|
BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients
Investors might be finally recognizing the hidden value of the firms' drug research and development.
Results From a One-Year Study of Efficacy and Safety of Aimovig in Chronic Migraine and Data From a Three-Year Analysis Assessing Safety and Tolerability of Aimovig in Episodic Migraine Will be Presented at the American Headache Society Annual Meeting
$11 Billion is Estimated to be Lost by American Employers Each Year Due to Migraine
The My Migraine Voice Survey Involved More Than 11,000 People Globally, 10 Percent of Which Were From the U.S., and Highlights Urgent Need for Better Care for Benefit of Patients and Society
Study Evaluated Efficacy and Safety of ABP 710 Compared With Infliximab in Patients With Moderate-to-Severe Rheumatoid Arthritis
Data Presented at the 78th Scientific Sessions of the American Diabetes Association
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy
While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.
The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months
Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures
THOUSAND OAKS, Calif., June 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39 th Annual Global Healthcare Conference at 9:30 a.
Amgen's First Public-Private Partnership with a State Medicaid Agency to Help Improve Patient Health Care Needs Through Data, Science and Information
Stocks are mixed Tuesday but traders continue to snap up tech stocks.
Jim Cramer talks about the stocks and sectors behind the resurgence fueling the Nasdaq's gains.
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
Jim Cramer says the market like this economy; he has your game plan for next week.
Less Frequent Once-Weekly KYPROLIS Regimen Also Significantly Increased Overall Response Rates With a Comparable Safety Profile Versus a Twice-Weekly Regimen
Efforts to Focus on Pre-Clinical and Clinical Research for up to 16 Early-Stage Programs Across Various Types of Cancer
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMGN, CIG.C, COTV, CTRE, GMS, HPT, IAG, NFEC, QGEN, SCVL, THR, TPHS, USFD, UVV Downgrades: BKE, IGT, TSLX, VRX Initiations: MGEN Read on to get TheStreet Quant Ratings' detailed report:
Public-Private Partnership Aims to Connect Underserved Cancer Patients to Enhanced Symptom Management Support Through the Use of Connected Technologies
Options spreads aren't tradable with some small biotechs, making shares the only way to play.
Here's what you need to know now for Friday, May 18.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.